nor-NOHA acetate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H530935

CAS#: 1140844-63-8 (acetate)

Description: nor-NOHA is a potent, selective, competitive, and high affinity inhibitor of arginase. nor-NOHA inhibits arginase from rat liver (IC50 = 2 µM) and mouse macrophages (IC50 = 50 µM).

Chemical Structure

img
nor-NOHA acetate
CAS# 1140844-63-8 (acetate)
Instruction

Theoretical Analysis

Hodoodo Cat#: H530935
Name: nor-NOHA acetate
CAS#: 1140844-63-8 (acetate)
Chemical Formula: C9H20N4O7
Exact Mass: 0.00
Molecular Weight: 296.280
Elemental Analysis: C, 36.49; H, 6.80; N, 18.91; O, 37.80

Price and Availability

Size Price Availability Quantity
5mg USD 250 2 Weeks
10mg USD 450 2 Weeks
50mg USD 1150 2 Weeks
Bulk inquiry

Related CAS #: 189302-40-7 (free base)   1140844-63-8 (acetate)   291758-32-2 (HCl)    

Synonym: nor-NOHA acetate, N(ω)-hydroxy-nor-L-arginine.

IUPAC/Chemical Name: (2S)-2-Amino-(4-(2ʹ-hydroxyguanidino))butyric Acid; acetic acid (1:2)

InChi Key: PQFYTZJPYBMTCT-QTNFYWBSSA-N

InChi Code: InChI=1S/C5H12N4O3.2C2H4O2/c6-3(4(10)11)1-2-8-5(7)9-12;2*1-2(3)4/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9);2*1H3,(H,3,4)/t3-;;/m0../s1

SMILES Code: O=C(O)[C@@H](N)CCN/C(N)=N/O.CC(O)=O.CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 296.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Havlínová Z, Hroch M, Nagy A, Sišpera L, Holeček M, Chládek J. Single- and multiple-dose pharmacokinetics of arginase inhibitor Nω-hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats. Gen Physiol Biophys. 2014;33(2):189-98. doi: 10.4149/gpb_2013078. Epub 2013 Oct 31. PubMed PMID: 24177023.

2: Hu H, Moon J, Chung JH, Kim OY, Yu R, Shin MJ. Arginase inhibition ameliorates adipose tissue inflammation in mice with diet-induced obesity. Biochem Biophys Res Commun. 2015 Aug 28;464(3):840-7. doi: 10.1016/j.bbrc.2015.07.048. Epub 2015 Jul 16. PubMed PMID: 26188090.

3: Rodríguez-Gómez I, Manuel Moreno J, Jimenez R, Quesada A, Montoro-Molina S, Vargas-Tendero P, Wangensteen R, Vargas F. Effects of Arginase Inhibition in Hypertensive Hyperthyroid Rats. Am J Hypertens. 2015 Dec;28(12):1464-72. doi: 10.1093/ajh/hpv049. Epub 2015 Apr 23. PubMed PMID: 25907224.

4: Havlinova Z, Babicova A, Hroch M, Chladek J. Comparative pharmacokinetics of N(ω)-hydroxy-nor-L-arginine, an arginase inhibitor, after single-dose intravenous, intraperitoneal and intratracheal administration to brown Norway rats. Xenobiotica. 2013 Oct;43(10):886-94. doi: 10.3109/00498254.2013.780672. Epub 2013 Mar 21. PubMed PMID: 23517541.

5: Risse PA, Lavoie-Lamoureux A, Jo T, Tsuchiya K, Siddiqui S, Martin JG. Airway arginase expression and Nω-hydroxy-nor-arginine effect on methacholine-induced bronchoconstriction differentiate Lewis and Fischer rat strains. J Appl Physiol (1985). 2014 Mar 15;116(6):621-7. doi: 10.1152/japplphysiol.01241.2013. Epub 2014 Feb 6. PubMed PMID: 24505101.

6: Reid KM, Tsung A, Kaizu T, Jeyabalan G, Ikeda A, Shao L, Wu G, Murase N, Geller DA. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G512-7. Epub 2006 Oct 5. PubMed PMID: 17023552.

7: Li H, Meininger CJ, Bazer FW, Wu G. Intracellular sources of ornithine for polyamine synthesis in endothelial cells. Amino Acids. 2016 Oct;48(10):2401-10. doi: 10.1007/s00726-016-2256-6. Epub 2016 May 14. PubMed PMID: 27180260.

8: Prati C, Berthelot A, Kantelip B, Wendling D, Demougeot C. Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther. 2012 May 30;14(3):R130. doi: 10.1186/ar3860. PubMed PMID: 22647483; PubMed Central PMCID: PMC3446511.

9: Bagnost T, Guillaume YC, Thomassin M, Robert JF, Berthelot A, Xicluna A, André C. Immobilization of arginase and its application in an enzymatic chromatographic column: thermodynamic studies of nor-NOHA/arginase binding and role of the reactive histidine residue. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):113-20. Epub 2007 Jun 2. PubMed PMID: 17588506.

10: Lasch M, Caballero-Martinez A, Troidl K, Schloegl I, Lautz T, Deindl E. Arginase inhibition attenuates arteriogenesis and interferes with M2 macrophage accumulation. Lab Invest. 2016 Aug;96(8):830-8. doi: 10.1038/labinvest.2016.62. Epub 2016 May 30. PubMed PMID: 27239731.

11: Bagnost T, Guillaume YC, Thomassin M, Berthelot A, Demougeot C, André C. Biochromatographic framework for analyzing magnesium chloride salt dependence on nor-NOHA binding to arginase enzyme. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 15;873(1):37-40. doi: 10.1016/j.jchromb.2008.07.024. Epub 2008 Jul 29. PubMed PMID: 18723409.

12: Arıkan-Ayyıldız Z, Karaman M, Tuncel T, Kiray M, Bağrıyanık A, Yilmaz O, Uzuner N, Karaman O. Beneficial effects of arginase inhibition and inhaled L-arginine administration on airway histology in a murine model of chronic asthma. Allergol Immunopathol (Madr). 2014 Jul-Aug;42(4):316-23. doi: 10.1016/j.aller.2013.01.001. Epub 2013 Apr 8. PubMed PMID: 23578782.

13: Tratsiakovich Y, Gonon AT, Krook A, Yang J, Shemyakin A, Sjöquist PO, Pernow J. Arginase inhibition reduces infarct size via nitric oxide, protein kinase C epsilon and mitochondrial ATP-dependent K+ channels. Eur J Pharmacol. 2013 Jul 15;712(1-3):16-21. doi: 10.1016/j.ejphar.2013.04.044. Epub 2013 May 9. PubMed PMID: 23665492.

14: Li X, Zhu F, He Y, Luo F. [Arginase inhibitor nor-NOHA induces apoptosis and inhibits invasion and migration of HepG2 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Apr;33(4):477-482. Chinese. PubMed PMID: 28395717.

15: Ogino K, Kubo M, Takahashi H, Zhang R, Zou Y, Fujikura Y. Anti-inflammatory effect of arginase inhibitor and corticosteroid on airway allergic reactions in a Dermatophogoides farinae-induced NC/Nga mouse model. Inflammation. 2013 Feb;36(1):141-51. doi: 10.1007/s10753-012-9529-3. PubMed PMID: 22915279.

16: Gonon AT, Jung C, Katz A, Westerblad H, Shemyakin A, Sjöquist PO, Lundberg JO, Pernow J. Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS One. 2012;7(7):e42038. doi: 10.1371/journal.pone.0042038. Epub 2012 Jul 31. PubMed PMID: 22860052; PubMed Central PMCID: PMC3409239.

17: Shemyakin A, Kövamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, Jung C, Pernow J. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation. 2012 Dec 18;126(25):2943-50. doi: 10.1161/CIRCULATIONAHA.112.140335. Epub 2012 Nov 26. PubMed PMID: 23183942.

18: Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999 Dec;3(6):427-38. PubMed PMID: 10637120.

19: Bratt JM, Franzi LM, Linderholm AL, O'Roark EM, Kenyon NJ, Last JA. Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol. 2010 Jan 1;242(1):1-8. doi: 10.1016/j.taap.2009.09.018. Epub 2009 Oct 2. PubMed PMID: 19800904; PubMed Central PMCID: PMC3221650.

20: Huynh NN, Harris EE, Chin-Dusting JF, Andrews KL. The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol. 2009 Jan;156(1):84-93. doi: 10.1111/j.1476-5381.2008.00036.x. PubMed PMID: 19133993; PubMed Central PMCID: PMC2697778.